Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
An Open-Label Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Corvus Pharmaceuticals, Inc.
This PHASE1 trial investigates Multiple Myeloma and is currently completed. Corvus Pharmaceuticals, Inc. leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Oct 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Jul 2020 [monthly]
Recruiting PHASE1
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Corvus Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .